TY - JOUR
T1 - Notch Signaling Facilitates In Vitro Generation of Cross-Presenting Classical Dendritic Cells
AU - Kirkling, Margaret E.
AU - Cytlak, Urszula
AU - Lau, Colleen M.
AU - Lewis, Kanako L.
AU - Resteu, Anastasia
AU - Khodadadi-Jamayran, Alireza
AU - Siebel, Christian W.
AU - Salmon, Hélène
AU - Merad, Miriam
AU - Tsirigos, Aristotelis
AU - Collin, Matthew
AU - Bigley, Venetia
AU - Reizis, Boris
N1 - Funding Information:
We gratefully acknowledge the participation of healthy donors and patients. We thank Ioannis Aifantis, Stefan Feske, and their lab members for reagents and advice; Juan Carlos Zúñiga-Pflücker and the Sunnybrook Research Institute for OP9-DL1/4 cells; and Hans Hacker for HoxB8-FL cells. We acknowledge the Newcastle University Flow Cytometry Core Facility, the NYU Genome Technology Center (GTC), and NYU Applied Bioinformatics Facility Laboratories (ABL). This work has used computing resources at the NYU High Performance Computing Facility (HPCF). The GTC and ABL are shared resources partially supported by NIH grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center. This work was supported by NIH grants AI072571, AG049074, and AI115382 (to B.R.); AI100853 (to C.M.L.); and AI124661 (to M.E.K.); Wellcome Trust 101155/Z/13/Z (to V.B. and U.C.), CRUK C30484/A21025 (to M.C.), and the NIHR Newcastle Biomedical Research Centre (to V.B., U.C., and M.C.).
Funding Information:
We gratefully acknowledge the participation of healthy donors and patients. We thank Ioannis Aifantis, Stefan Feske, and their lab members for reagents and advice; Juan Carlos Zúñiga-Pflücker and the Sunnybrook Research Institute for OP9-DL1/4 cells; and Hans Hacker for HoxB8-FL cells. We acknowledge the Newcastle University Flow Cytometry Core Facility, the NYU Genome Technology Center (GTC), and NYU Applied Bioinformatics Facility Laboratories (ABL). This work has used computing resources at the NYU High Performance Computing Facility (HPCF). The GTC and ABL are shared resources partially supported by NIH grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center. This work was supported by NIH grants AI072571 , AG049074 , and AI115382 (to B.R.); AI100853 (to C.M.L.); and AI124661 (to M.E.K.); Wellcome Trust 101155/Z/13/Z (to V.B. and U.C.), CRUK C30484/A21025 (to M.C.), and the NIHR Newcastle Biomedical Research Centre (to V.B., U.C., and M.C.).
Publisher Copyright:
© 2018 The Authors
PY - 2018/6/19
Y1 - 2018/6/19
N2 - The IRF8-dependent subset of classical dendritic cells (cDCs), termed cDC1, is important for cross-priming cytotoxic T cell responses against pathogens and tumors. Culture of hematopoietic progenitors with DC growth factor FLT3 ligand (FLT3L) yields very few cDC1s (in humans) or only immature “cDC1-like” cells (in the mouse). We report that OP9 stromal cells expressing the Notch ligand Delta-like 1 (OP9-DL1) optimize FLT3L-driven development of cDC1s from murine immortalized progenitors and primary bone marrow cells. Co-culture with OP9-DL1 induced IRF8-dependent cDC1s with a phenotype (CD103+ Dec205+ CD8α+) and expression profile resembling primary splenic cDC1s. OP9-DL1-induced cDC1s showed preferential migration toward CCR7 ligands in vitro and superior T cell cross-priming and antitumor vaccination in vivo. Co-culture with OP9-DL1 also greatly increased the yield of IRF8-dependent CD141+ cDC1s from human bone marrow progenitors cultured with FLT3L. Thus, Notch signaling optimizes cDC generation in vitro and yields authentic cDC1s for functional studies and translational applications. Dendritic cells (DCs) are critical inducers of immune responses, but current methods to generate them in vitro are suboptimal. Kirkling et al. report that Notch signaling facilitates the generation of DCs that closely resemble their in vivo counterparts and show superior capacity to vaccinate against tumors in vivo.
AB - The IRF8-dependent subset of classical dendritic cells (cDCs), termed cDC1, is important for cross-priming cytotoxic T cell responses against pathogens and tumors. Culture of hematopoietic progenitors with DC growth factor FLT3 ligand (FLT3L) yields very few cDC1s (in humans) or only immature “cDC1-like” cells (in the mouse). We report that OP9 stromal cells expressing the Notch ligand Delta-like 1 (OP9-DL1) optimize FLT3L-driven development of cDC1s from murine immortalized progenitors and primary bone marrow cells. Co-culture with OP9-DL1 induced IRF8-dependent cDC1s with a phenotype (CD103+ Dec205+ CD8α+) and expression profile resembling primary splenic cDC1s. OP9-DL1-induced cDC1s showed preferential migration toward CCR7 ligands in vitro and superior T cell cross-priming and antitumor vaccination in vivo. Co-culture with OP9-DL1 also greatly increased the yield of IRF8-dependent CD141+ cDC1s from human bone marrow progenitors cultured with FLT3L. Thus, Notch signaling optimizes cDC generation in vitro and yields authentic cDC1s for functional studies and translational applications. Dendritic cells (DCs) are critical inducers of immune responses, but current methods to generate them in vitro are suboptimal. Kirkling et al. report that Notch signaling facilitates the generation of DCs that closely resemble their in vivo counterparts and show superior capacity to vaccinate against tumors in vivo.
UR - http://www.scopus.com/inward/record.url?scp=85048553213&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2018.05.068
DO - 10.1016/j.celrep.2018.05.068
M3 - Article
C2 - 29925006
AN - SCOPUS:85048553213
SN - 2211-1247
VL - 23
SP - 3658-3672.e6
JO - Cell Reports
JF - Cell Reports
IS - 12
ER -